NCT06791044 25(OH)-Vitamin D and Its Association With Structural and Functional Parameters in Hospitalized Patients With Neurological Diseases
| NCT ID | NCT06791044 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dionyssiotis, Yannis, M.D. |
| Condition | Vitamin D Insufficiency |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2025-09-01 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The NeuroVitD study aims to assess vitamin D levels in hospitalized cohorts with neurological disorders resulting in motor disabilities, providing epidemiological data necessary for guidelines. The primary objective is to assess vitamin D insufficiency in the neurological populations under investigation and secondary to evaluate the impact of vitamin D supplementation on problems associated with structural and functional parameters. The NeuroVitD study will be a randomized, cluster, controlled intervention trial lasting 2 years, enrolling 120 individulas, (30 controls), including those with stroke, spinal cord injury, and traumatic brain injury. Comprehensive epidemiological data, including demographic and anthropometric information, will be documented alongside social behaviors such as exercise and smoking. Serum vitamin D levels, bone density, body composition, strength, speed, physical performance and pain will be assessed. The study will also evaluate the effects of vitamin D supplementation at two distinct dosages: 50,000 I.U of vitamin D weekly for 8 weeks or 25,000 I.U of vitamin D for 4 weeks followed by 10,000 I.U of vitamin D drops weekly for an additional 4 weeks. Calcium, parathyroid hormone, and phosphorus levels will be assessed to examine the impact of vitamin D administration on additional biochemical markers. The findings will encompass vitamin D levels, bone density, body composition, strength, walking speed, physical performance and pain. The impact of vitamin D supplementation on various biochemical parameters will be analyzed, along with gender and group comparisons. Correlations will be established based on participants' residential locations, the administration of vitamin D supplementation, seasonal variations, and associations with specific medications for neurological conditions.
Eligibility Criteria
Inclusion Criteria: * populations with neurological disorders * healthy volunteers (controls) Exclusion Criteria: * The subject is excluded if they: * are legally or mentally incapable of comprehending and consenting to participate in the study * have a history of or exhibit indicators of metabolic bone disease, including the following: Hypoparathyroidism, primary hyperparathyroidism, recent hyperthyroidism (within the last six months), Paget's disease of bone; * grade 3 or 4 pressure ulcers present; * has undergone treatment with pharmacological agents influencing bone metabolism prior to the initial bone density assessment, including the following: bisphosphonates in the year prior to the bone density assessment ; parathyroid hormone in the year prior to the research ; estrogens, selective estrogen receptor modulators (SERMs), tibolone, or anabolic steroids within the preceding six months. * Thyroid drugs are permissible only if the dosage has remained consistent for the preceding six weeks and TSH levels are within the normal range. * Corticosteroid medication exceeding 7.5 mg of prednisone orally per day for a duration exceeding one month within the past six months. * Immunosuppressant therapy within the past year; * Vitamin A therapy above 10,000 IU per day or Vitamin D exceeding 5,000 IU per day. * Participants are prohibited from consuming additional vitamin D supplements exceeding 400 IU per day or traveling to regions with heightened sunshine exposure during the trial.
Contact & Investigator
Yannis Dionyssiotis
STUDY CHAIR
National Rehabilitation Center EKA
Frequently Asked Questions
Who can join the NCT06791044 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 85 Years, studying Vitamin D Insufficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06791044 currently recruiting?
Yes, NCT06791044 is actively recruiting participants. Contact the research team at yannis_dionyssiotis@hotmail.com for enrollment information.
Where is the NCT06791044 trial being conducted?
This trial is being conducted at Nea Liosia, Greece, Athens, Greece.
Who is sponsoring the NCT06791044 clinical trial?
NCT06791044 is sponsored by Dionyssiotis, Yannis, M.D.. The principal investigator is Yannis Dionyssiotis at National Rehabilitation Center EKA. The trial plans to enroll 120 participants.